The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-15
Target enrollment:
Participant gender:
Summary
This is a phase II, prospective, multicenter, study to evaluate the recurrence gene profiles of adjuvant osimertinib therapy in resected EGFR-mutated NSCLC.